English
Human pluripotent stem cells have traditionally been derived from surplus embryos and termed human embryonic stem cells (hESCs). However, it has recently been shown that adult human somatic cells can be reprogrammed to a pluripotent state. These reprogrammed cells are known as induced pluripotent stem (iPS) cells. Human iPS cell research is still at a very early stage compared to hESC research, with many fundamental questions on how these cells and their differentiated derivatives compare to hESCs remaining to be answered. This project aims to investigate the ability of iPS cells to differentiate into cells of the cardiovascular lineage, and compare these cells to similar cardiac populations derived from hESCs. A genetically engineered human iPS cell line will be made, providing both a readout for cardiomyocyte differentiation efficiency and enabling pure populations of cardiac progenitor cells to be isolated. Because we already have access to an identical genetically engineered line in hESCs, I will be able to compare purified populations of cardiac cells from both stem cell sources, not just functionally but also at the epigenetic and proteomic level.
